by Plus Therapeutics | Oct 27, 2025 | Uncategorized
Last weekend, members of the Plus Therapeutics team — led by Gabby Cleveland — participated in the 7th Annual Head for the Cure Foundation 5K in Phoenix, Arizona, standing alongside patients, caregivers, and advocates united in the fight against brain cancer. This...
by Plus Therapeutics | Oct 23, 2025 | Uncategorized
Plus Therapeutics’ President & CEO, Marc Hedrick, M.D., was recently featured as a key opinion leader in a Nature Cancer article by Melanie Senior highlighting how biotechnology companies are advancing the next generation of radiopharmaceutical therapies ahead of...
by Plus Therapeutics | Oct 15, 2025 | PBC
Designing clinical trials for children isn’t as simple as shrinking adult trials — and that’s exactly why awareness and advocacy matter. Pediatric cancers are rare, meaning fewer patients to enroll, longer trial timelines, and unique ethical and medical challenges...
by Plus Therapeutics | Oct 14, 2025 | LM
Last week, CNSide® Medical Director Jonathan Stein, PhD, HCLD(ABB) presented at BioHouston’s October Life Science event — joining Houston’s growing network of researchers, entrepreneurs, and clinicians driving the future of biotech innovation. The discussion centered...
by Plus Therapeutics | Oct 13, 2025 | LM
Did you know that as many as 5% to 20% of people with advanced breast cancer may eventually develop leptomeningeal metastases (LM) — also known as leptomeningeal disease (LMD)? LM occurs when cancer cells spread to the membranes (meninges) that surround the brain and...
Recent Comments